Skip to main content
FutureChem Co., Ltd. logo

FutureChem Co., Ltd. — Investor Relations & Filings

Ticker · 220100 ISIN · KR7220100002 KO Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2022-12-29 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 220100

About FutureChem Co., Ltd.

https://www.futurechem.co.kr/?language=…

FutureChem Co., Ltd. is a company specializing in the development and production of radiopharmaceuticals for diagnostic and therapeutic applications. The company's operations cover the manufacturing of radiopharmaceutical precursors, chemical compounds, synthesis reagents, and automated synthesis modules. Its product pipeline focuses on agents for the diagnosis and treatment of various cancers and neurological disorders, including Parkinson's disease. FutureChem supports the broader radiopharmaceutical field by providing both finished products and the essential chemical building blocks and equipment required for their synthesis. The company actively establishes global partnerships for clinical supply and commercial licensing of its technologies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like Director's Dealing (which is for personal trades) or Share Issue (which is for actual capital changes).
2022-12-29 Korean
투자판단관련주요경영사항(재발 또는 전이가 의심되는 전립선암 환자에서의 [18F]Florastamin PET/CT 영상검사의 진단 유효성 및 안전성을 평가하기 위한 다기관, 단일군, 공개, 제3상 임상시험계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the approval of a Phase III clinical trial by the Ministry of Food and Drug Safety. Since this is a specific regulatory announcement regarding company operations (clinical trial status) that does not fit into financial reporting, dividend, or governance categories, it is classified as a Regulatory Filing (RNS).
2022-12-27 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the procedural steps for the meeting. Given it is a regulatory announcement regarding meeting logistics, it falls under the RNS category.
2022-12-15 Korean
투자판단관련주요경영사항(전립선암 진단용 [F-18]Florastamin 방사성의약품 FC303 의 중국 임상 3상 IND 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean company FutureChem regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically details the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial of their prostate cancer diagnostic agent in China. Since this is a specific regulatory disclosure regarding clinical trial progress and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2022-11-30 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company FutureChem (주)퓨쳐켐, covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
[기재정정]증권발행실적보고서
Capital/Financing Update Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed by FutureChem. This document is a mandatory regulatory filing in South Korea (DART system) that details the final results of a capital increase (rights offering), including share issuance, subscription results, and the use of proceeds. It is not an announcement of a report, but the report itself, and it fits the definition of a capital/financing update regarding the company's capital structure changes.
2022-11-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.